Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia
Enfermedades infecciosas y microbiologia clinica (English ed.) · 2023
DOI: 10.1016/j.eimce.2022.07.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2023. Verfasst von Letícia Kraft und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Emerging Infectious Diseases, School of Medicine, Department of Health Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, …. Hauptthemen laut MEDLINE: Amphotericin B, Candidemia. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Biofilm formation causes virulence and resistance in Candida albicans. However, little is known about breakthrough candidemia isolates. We evaluated the antifungal activity of fluconazole, anidulafungin, deoxycholate amphotericin B (dAMB), and amphotericin B lipid complex (ABLC) against biofilms of C. albicans isolated from patients with breakthrough candidemia. METHODS: The present study used strains of C. albicans isolated from breakthrough and non-breakthrough candidemia patients (control group). The susceptibility of planktonic cells to amphotericin B, anidulafungin, and fluconazole was determined by broth microdilution. Antifungal activity in sessile cells was evaluated using the minimum biofilm eradication concentration (MBEC), metabolic activity was estimated by reducing MTT, and biomass was estimated using crystal violet retention. RESULTS: The planktonic strains were susceptible to amphotericin B, anidulafungin, and fluconazole, with minimum inhibitory concentrations of 1, ≤0.03, and 2mg/L, respectively. However, fluconazole and anidulafungin did not exert an antifungal effect on biofilms. Additionally, dAMB and ABCL reduced the metabolic activity and biomass. However, eradication was only achieved using 16mg/L dAMB. C. albicans isolates of breakthrough candidemia exhibited strong biofilm production, and the in vitro activity of available therapeutic options was poor. CONCLUSION: In the present study, only dAMB and ABCL exhibited antibiofilm effects against sessile breakthrough candidemia isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Emerging Infectious Diseases, School of Medicine, Department of Health Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil.
- Laboratory of Emerging Infectious Diseases, School of Medicine, Department of Health Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil. Electronic address: felipe.tuon@pucpr.br.
Zitieren
APA
Kraft, L., Ribeiro, V. S. T., Gonçalves, G. A., Suss, P. H., & Tuon, F. F. (2023). Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2022.07.009
Vancouver
Kraft L, Ribeiro VST, Gonçalves GA, Suss PH, Tuon FF. Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia. Enfermedades infecciosas y microbiologia clinica (English ed.). 2023. doi:10.1016/j.eimce.2022.07.009
BibTeX
@article{Kraft2023,
author = {Kraft, Letícia and Ribeiro, Victoria Stadler Tasca and Gonçalves, Geiziane Aparecida and Suss, Paula Hansen and Tuon, Felipe Francisco},
title = {Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia},
journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
year = {2023},
doi = {10.1016/j.eimce.2022.07.009}
}
EUVIMED